Yuko Mizuma – GM, Hong Kong & Macau, Eli Lilly Asia, Inc.
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Disease and Respiratory. We are also selectively active in the areas of autoimmunity, neuroscience and infection. Its presence in Hong Kong – in the name of AstraZeneca Hong Kong – can be traced back to 1999 when AstraZeneca was formed following a merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Both companies were established in Hong Kong in the 1970s.
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since our establishment, we have been focusing on identifying and bringing in the latest medical solutions as well as seeking ongoing business development. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
Contact
Address: Unit 1-3, 11/F, 18 King Wah Road, North Point
Tel: +(852) 2420 7388
Website: https://www.astrazeneca.com/country-sites/hong-kong.html
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
Drawing on an extensive management background in telecom, IT, and digital, Vincent Ma now serves as CEO of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). He outlines the under-construction…
Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology…
OASES was established to position Hong Kong as a global innovation and technology hub, with significant investments in infrastructure and funding, particularly focusing on life and health sciences, AI, fintech,…
One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing…
A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s…
The City University of Hong Kong (CityUHK) has a well-earned reputation as an innovative hub for research and professional education. Michael Yang, Senior VP of Innovation and Enterprise, professor of…
Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the…
Dr Juliana Chan, one of Asia’s leading endocrinologists, is also the founding director of GemVCare, a company that provides data to medical professionals to advise patients on diabetes prevention, diagnosis, and…
Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom…
Arbele is a clinical stage biotech centred on an innovative T-Cell Engager approach to gastrointestinal cancers. Chairman and founder John Luk explains the prevalence of these cancers in China, the…
Sabrina Chan, senior executive director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI), an organization that represents the innovative pharmaceutical industry in Hong Kong and Macau, weighs in…
See our Cookie Privacy Policy Here
